Keywords: fda, advisory, panel, votes, keep, gsk, avandia
FDA advisory panel votes to keep GSK's Avandia on US market but with warnings
Article | 06 August 2007
UK pharmaceutical giant GlaxoSmithKline received a welcome reprieve for its recently-battered type 2 diabetes drug Avandia (rosiglitazone), when a joint meeting ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
